Status:
NOT_YET_RECRUITING
R21/MM Dosing, Presentations, and Preservatives
Lead Sponsor:
University of Oxford
Conditions:
Plasmodium Falciparum Malaria
Malaria
Eligibility:
All Genders
14-60 years
Phase:
PHASE4
Brief Summary
This is a single blind randomised controlled trial. This study aims to assess whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in child and adults. The results ...
Eligibility Criteria
Inclusion
- Residence in a study village for the study period, i.e. 12 months.
- Age 14 years to 60 years.
- Written informed consent/assent provided by participants (or a parent/guardian in case the participant is under 18 years old).
Exclusion
- Pregnancy, plan to get pregnant within one month of vaccination, or breastfeeding.
- Acute illness requiring intervention.
- A history of an adverse reaction to study vaccine.
- Prior receipt of any other malaria vaccine.
- Enrolment in another intervention trial in the last month.
- Planned enrolment in another intervention trial in the coming 12 months.
- Regular use of Immunomodulating drugs e.g, Steroid, Methotrexate, Immunotherapy etc. in the past month and/or planned for the coming 12 months.
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
375 Patients enrolled
Trial Details
Trial ID
NCT07194668
Start Date
December 1 2025
End Date
December 31 2026
Last Update
November 19 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Lama Upazila Health Complex
Lāma, Lama, Bangladesh, 4641
2
Alikadam Upazila Health Complex
Bāndarban, Bangladesh, 4650